



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)
A61P 35/00 (2006.01) C07K 16/30 (2006.01)

(21) International Application Number:

PCT/US2020/050515

(22) International Filing Date:

11 September 2020 (11.09.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/901,364	17 September 2019 (17.09.2019)	US
62/985,509	05 March 2020 (05.03.2020)	US
63/047,824	02 July 2020 (02.07.2020)	US
63/058,016	29 July 2020 (29.07.2020)	US

(71) Applicant: **APEXIGEN, INC.** [US/US]; 75 Shoreway Road, Suite C, San Carlos, California 94070 (US).

(72) Inventors: **FILBERT, Erin L.**; c/o Apexigen, Inc., 75 Shoreway Road, Suite C, San Carlos, California 94070

(US). **KRISHNAN, Sushma**; c/o Apexigen, Inc., 75 Shoreway Road, Suite C, San Carlos, California 94070 (US). **TAN, Christine**; c/o Apexigen, Inc., 75 Shoreway Road, Suite C, San Carlos, California 94070 (US). **BAHJAT, Rena**; c/o Apexigen, Inc., 75 Shoreway Road, Suite C, San Carlos, California 94070 (US). **YANG, Xiaodong**; c/o Apexigen, Inc., 75 Shoreway Road, Suite C, San Carlos, California 94070 (US). **ALVARADO, Ryan**; c/o Apexigen, Inc., 75 Shoreway Road, Suite C, San Carlos, California 94070 (US).

(74) Agent: **CHRISTIANSEN, William** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: ANTI-TNFR2 ANTIBODIES AND METHODS OF USE




FIG. 1

(57) Abstract: Provided are anti-tumor necrosis factor receptor 2 (TNFR2) antibodies and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of oncological diseases, inflammatory and/or autoimmune diseases, and others. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, does not substantially bind to TNFR1, herpesvirus entry mediator (HVEM), CD40, death receptor 6 (DR6), and/or osteoprotegerin (OPG).

[Continued on next page]

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

29 April 2021 (29.04.2021)